Bio-Outsourcing

Oxford Biomedica receives £53.5m injection from Novo Holdings

30-May-2019 By Vassia Barba

Novo Holdings invests £53.5m in Oxford Biomedica, funds which the company will use to further develop its LentiVector platform for cell and gene therapies.

Evotec jumps into biologics through $90m Just.Bio acquisition

29-May-2019 By Vassia Barba

Evotec to join the emerging biologics market through Just Biotherapeutics’ smart technology platforms, machine learning tools and low cost manufacturing facilities.

Cryoport expands into biostorage with Cryogene acquisition

23-May-2019 By Vassia Barba

Cryoport acquires Cryogene to gain access to the latter company’s 21,000-square-foot biostorage facility in Houston.

WuXi in $3bn deal to manufacture 'first of its kind' vaccine

23-May-2019 By Vassia Barba

WuXi Vaccines will build a dedicated manufacturing facility for an unnamed global vaccine leader, under a 20-year contract.

US Senate authorises increased spending on pandemic flu products

23-May-2019 By Nick Taylor

The Senate has passed a bill authorising spending on the development of products to protect the US against pandemic influenza and other biological threats to public health.

Lonza adopts Synpromics’ inducible promoters, expands bio manufacturing platform

22-May-2019 By Vassia Barba

Lonza and Synpromics move on to the commercialization of a number of inducible promoters to expand the former’s manufacturing offerings.

Small businesses the ‘bedrock’ that allow for innovation

20-May-2019 By Ben Hargreaves

There are 1,500 SME medicine discovery companies in the UK and more than half are working on non-small molecule therapeutics, a Catapult report finds.

Immunologix boosts Translational Sciences division with new recruits

13-May-2019 By Maggie Lynch

Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.

Kite gets freedom to fly after separation from Gilead

08-May-2019 By Vassia Barba

Gilead’s new CEO unties Kite as an independent business unit to give Yescarta’s manufacturer more autonomy in the biotech sky.

Lonza serves small biotech with services to accelerate movement to the clinic

06-May-2019 By Maggie Lynch

Lonza announces service offering to accelerate the movement of poorly-soluble small molecules into first-in-human clinical trials.

GeneDesign opens large-scale production facility in Osaka

23-Apr-2019 By Vassia Barba

The Ajinomoto subsidiary opens a development and production base for oligonucleotide drug substances in Japan.

New consultancy targets ‘expansive global landscape’ for cell and gene therapies

01-Apr-2019 By Melissa Fassbender

Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.

MaSTherCell brings ‘large-scale’ advanced therapeutics manufacturing to Europe

28-Mar-2019 By Ben Hargreaves

The CDMO leases a facility in Belgium to manufacture cell and gene therapies at a large-scale, in a move the company claims is a first in Europe.

Biocon receives Form 483 due to risk of contamination

13-Mar-2019 By Ben Hargreaves

The US FDA issues Biocon a Form 483 with two observations, including failure to establish proper aseptic practices and lack of follow-up on data discrepancies.

Fujifilm continues ‘aggressive’ expansion with $890m site purchase

12-Mar-2019 By Ben Hargreaves

Fujifilm continues investment in its manufacturing capabilities through the acquisition of a large-scale biologics site from Biogen.

‘Can you manufacture consistently?’ The big question in regenerative medicine

11-Mar-2019 By Ben Hargreaves

Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.

GE Healthcare working ‘two to three years’ ahead anticipating manufacturing advances

06-Mar-2019 By Ben Hargreaves

The rapid evolution of cell and gene therapy technology is leading GE Healthcare to explore partnerships to meet increasing manufacturing demand, according to the company's enterprise solutions leader.

GE continues slim down with $21bn sale of BioPharma business

25-Feb-2019 By Ben Hargreaves

GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.

WuXi Biologics expects to receive EU GMP nod in matter of months

21-Feb-2019 By Ben Hargreaves

The EMA completes pre-approval inspection of WuXi Biologics facilities, raising no critical issues for the Chinese company.

WuXi Biologics enters first commercial manufacturing agreement

13-Feb-2019 By Ben Hargreaves

WuXi Biologics agrees five-year deal with Amicus for the commercial production of a biologic for the treatment of Pompe disease.

CAR-T for solid tumors drives industry to innovate

08-Feb-2019 By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

Five reasons biologics contract manufacturing will hit $87.6bn by 2027

25-Jan-2019 By Ben Hargreaves

The contract market for bringing biologics through the pipeline to commercialisation is growing at a rapid clip, with a recent report suggesting a high CAGR in the sector.

Boehringer expands commercial biologics production capacity in China

22-Jan-2019 By Ben Hargreaves

Boehringer will increase its capacity for commercial manufacturing of biologics at its Shanghai, China, facility.

NEWS IN BRIEF

Biologics CDMO completes €5m expansion in Spain

18-Dec-2018 By Staff Reporter

Biologics and cell therapy CDMO, 3P Biopharmaceuticals, has expanded its facility and capabilities in Pamplona, Spain.

Q&A

Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

10-Dec-2018 By Flora Southey

According to the lentiviral vector manufacturer, which supplies vectors for Novartis’ Kymriah, the market is growing – and could be worth $800m by 2026.

WuXi Biologics: Ireland’s largest single-use facility underway

07-Dec-2018 By Flora Southey

The CDMO has broken ground on its first site outside of China – a €325m single-use manufacturing facility in County Louth, Ireland.

Catalent expands biologics facility, to create 36 new jobs

04-Dec-2018 By Maggie Lynch

Catalent is expanding its US biologics packaging facility, following recent investments and expansions in the Asia-Pacific region.

WuXi Biologics wins ABL Bio contract for bispecific antibodies

29-Nov-2018 By Flora Southey

South Korean biotech ABL Bio has selected WuXi Biologics to develop and manufacture up to eight bispecific antibodies for the clinic.

Pall, Cobra and CGTC collaborate on continuous method for gene therapies

28-Nov-2018 By Flora Southey

Innovate UK has awarded £1.5m to three co-winners to investigate continuous manufacturing for AAV production.

Q&A

UK cell and gene therapy ecosystem ‘second to none’

26-Nov-2018 By Ben Hargreaves

The UK has a ‘rich and vibrant’ advanced therapeutic manufacturing sector well placed to attract companies post-Brexit, says Keith Thompson, CEO of CGTC.

WuXi Biologics announces new discovery, development and manufacturing site in China

23-Nov-2018 By Flora Southey

The CDMO has broken ground on its 1.6 million-square-foot Biologics Innovation Center in Shanghai.

Rentschler opens GMP fill/finish facility in Austria

21-Nov-2018 By Staff Reporter

Aseptic fill/finish contractor Rentschler Fill Solutions inaugurated the new facility in Austria’s eastern town of Rankweil.

ADC Bio secures funding to further manufacturing plans

16-Nov-2018 By Ben Hargreaves

The company announced an investment of £2.5m to design its downstream formulation and filling operations.

Q&A

Cryoport talks compliance, biopharma expansion, and Brexit

13-Nov-2018 By Flora Southey

Securing the clinical supply chain comes down to the notion of ‘compliance’, which is transitioning from a ‘nice to have’ to a ‘need to have,’ says Cryoport.

BIO Europe 2018

Medicon Valley: How Denmark and Sweden are ‘bridging’ the biotech gap

12-Nov-2018 By Flora Southey

The Nordic life science cluster aspires to become the most prominent in northern Europe, says Medicon Valley Alliance executive.

NEWS IN BRIEF

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

09-Nov-2018 By Flora Southey

Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.

BIO Europe 2018

#BIOEurope: ‘Deal making is off the charts and the IPO window is open’

08-Nov-2018 By Flora Southey

Denmark played host to its first BIO Europe this week, welcoming 4,500 attendees from across the globe – including growing numbers from China and South Korea.

Lonza invests in ‘game-changer’ automated cell therapy manufacture

31-Oct-2018 By Ben Hargreaves

After a three-year partnership, Lonza pulled the trigger on acquiring a controlling stake of Octane Biotech and their jointly developed Cocoon system.

Avid expansion to triple process development capacity, says CEO

25-Oct-2018 By Ben Hargreaves

Avid continues its transition to a fully-fledged CDMO by transforming its process development capabilities with new lab space.

BIA Bioscience Forum

Four major barriers to efficient cell & gene manufacture

22-Oct-2018 By Ben Hargreaves

BIA’s Bioscience Forum brought together four experts on cell and gene manufacture to discuss what difficulties are being faced in the industry and how they are reacting to them.

Berkeley Lights looks to CAR-T manufacture after securing $95m investment

19-Oct-2018 By Ben Hargreaves

This week Berkeley announced it had tied up a financing round and signed a cell line development deal with Selexis.

Lonza expands manufacturing sites for larger ADC payloads

16-Oct-2018 By Maggie Lynch

Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.

CBMG inks Kymriah deal: ‘China could take the lead in cell therapies’

15-Oct-2018 By Ben Hargreaves

CBMG announced a manufacturing collaboration agreement with Novartis at the end of last month to produce CAR-T treatment Kymriah for the Chinese market and the company has further ambitions in the pipeline.

CPhI Worldwide 2018

Samsung BioLogics opens third plant, contemplates a fourth in Korea

12-Oct-2018 By Flora Southey

The CDMO’s third biomanufacturing plant, regarded the world’s largest, is now operational in South Korea.

Mammalian plant a convenient option for growing Asian client base, says AGC

12-Oct-2018 By Flora Southey

AGC Biologics has announced plans to build a mammalian cell culture facility in Japan, where the company says demand is growing for antibody-based therapies.

NORDIC LIFE SCIENCE DAYS

Genetic disease drugmakers should sponsor at-home genetic tests, advises consultant

10-Oct-2018 By Flora Southey

Partnering with direct-to-consumer genetic testing firms will improve market access to gene-related disease therapies, says life sciences consultant.

NEWS IN BRIEF

BIA Separations adds upstream processing facility

28-Sep-2018 By Ben Hargreaves

BIA Separations has completed work on an additional upstream processing laboratory in Ajdovščina, Slovenia.

Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019

27-Sep-2018 By Melissa Fassbender

Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.

CHO cells the 1900s model car in a 2020 Tesla world, says Dyadic

24-Sep-2018 By Flora Southey

Dyadic’s CHO-alternative, the C1 production platform, could reduce time and cost at almost every stage of the cell development and biomanufacturing process, says CEO.